BACKGROUND: Early-stage and intermediate-stage nasopharyngeal cancer (NPC) generally carry a good prognosis, but for patients with recurrent, metastatic disease, options are limited. In the current study, the authors present a phase 1/2 study to evaluate the efficacy of Epstein-Barr virus (EBV)-stimulated cytotoxic T-lymphocyte (EBV-CTL) immunotherapy in this patient population. METHODS: Screening for patients with active, recurrent, metastatic EBV-associated NPC began in February 2007, and the study was closed to accrual in January 2012. After informed consent was obtained, patients had their blood drawn to initiate manufacturing of the EBV-CTL product. During product manufacturing, patients were placed on interim standard-of-care chemotherapy, and only after disease progression on the interim chemotherapy did patients receive investigational immunotherapy. Patients were restaged every 2 months until disease progression and then followed for survival. RESULTS: A total of 28 patients were enrolled, and 21 patients were treated. There was 1 complete response achieved, and at the time of last follow-up, the patient had been in remission for >8 years since treatment. The median progression-free survival was 2.2 months, and the median overall survival was 16.7 months. Two other patients, after failing EBV-CTL immunotherapy, unexpectedly demonstrated strong responses to the chemotherapy regimens they had previously failed. Patient EBV viral load and EBV-CTL specificity for tumor-associated viral antigens did not appear to correlate with clinical response. CONCLUSIONS: A durable response was observed with EBV-CTL immunotherapy, but the overall response rate for patients with recurrent, metastatic NPC was low. Further research is necessary to increase the efficacy of EBV-specific immunotherapy in patients with incurable NPC, and to characterize mechanisms for refacilitation to chemotherapy.
INTRODUCTION
Nasopharyngeal cancer (NPC) is linked to the Epstein-Barr virus (EBV) and is endemic in southern China and sub-Saharan Africa. Chemoradiotherapy is a highly effective standard of care with high cure rates in the majority of patients with locoregional disease. However, approximately one-third of patients are considered to be incurable because of metastatic disease at the time of presentation, recurrence with metastatic disease, or recurrence with local disease and no curative options. Unfortunately, prognosis has remained poor for these patients over the past decades. 1, 2 Combination chemotherapy with agents such as platinum, taxanes, and gemcitabine results in a median overall survival (OS) of 10 to 15 months, with overall response rates (ORRs) ranging from 25% to 79%. [3] [4] [5] [6] [7] [8] [9] Given these outcomes, the need for a more effective therapy for patients with incurable NPC is clear.
EBV is an attractive target for treatment because clonal, episomal EBV is found in approximately 95% of nonkeratinizing and undifferentiated NPC cases. In addition, EBV also is present in premalignant lesions, and is believed to be important for the oncogenic process in NPC. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] One strategy is to treat these tumors as immune targets and directly manipulate preexisting virusspecific cytotoxic T-lymphocytes (CTLs) to attack epitopes derived from viral proteins and presented by infected tumor cells. Prior studies have established the feasibility and safety of EBV-stimulated cytotoxic T-lymphocyte (EBV-CTL) immunotherapy in a variety of EBV-related neoplasms and proliferations, suggesting potential efficacy against NPC. In what to our knowledge is the earliest published study regarding EBV-specific immunotherapy in NPC, EBV-CTLs were administered to 4 patients with NPC. Although no measurable responses were observed, plasma EBV DNA samples were reduced to undetectable levels in all patients, thereby providing evidence of anti-EBV activity. 20 In 2004, Comoli et al reported on the treatment of a single patient with NPC using EBV-CTLs that resulted in a minimal reduction in tumor bulk, followed by 3 months of stable disease (SD). 21 In 2005, another clinical study by the same investigators evaluated EBV-specific immunotherapy in 10 patients with metastatic NPC who had failed conventional therapy and had developed progressive disease (PD). Two of these patients achieved partial responses (PRs) (3 months and 5 months, respectively) and 4 patients maintained SD (4 months, 4 months, 8 months, and 15 months, respectively). 22 In 2005, Straathof et al published a phase 1 study with EBVspecific adoptive immunotherapy in 10 patients diagnosed with stage III or stage IV NPC. Of 6 patients who received immunotherapy, 2 achieved complete responses (CRs) and 1 patient achieved a PR. 23 This phase 1 study was followed by a fixed-dose phase 2 component for 15 additional patients with NPC, resulting in an impressive ORR of 48.7%. 24 These last 3 studies used similar methods of producing EBV-specific CTLs, which involved repetitive stimulation of peripheral blood mononuclear cells (PBMCs) with autologous B cells that had been immortalized into lymphoblastoid cell lines (LCLs) using EBV.
However, in 2012, Smith et al tested an immunotherapy using T cells stimulated with an adenovirus-based vector targeting EBV-specific antigens expressed in NPC. The study reported a prolonged median OS for patients receiving this therapy versus patients not on the study (17.4 months vs 10.3 months), but did not observe any PRs or CRs. 2 Thus, although there is strong evidence of antitumor activity for EBV-specific immunotherapy in patients with NPC, response rates vary between the reported clinical trials. Contributing factors may include different technical approaches used for the generation of the EBV-CTLs, patient populations with different stages of disease, the impact of prior therapy, comorbid illnesses, or genetic predispositions. In the current phase 1/2 trial, we sought to evaluate the efficacy of an EBV-specific immunotherapy for patients with incurable NPC, with EBV-CTLs generated by stimulation with the patient's LCLs.
MATERIALS AND METHODS

Subjects
The studies were approved by the Institutional Review Board at the Dana-Farber Cancer Institute (DFCI) and registered with ClinicalTrials.gov (ClinicalTrials.gov identifiers NCT00431210 and NCT00834093). Patients were eligible if they had EBV-positive NPC as determined by EBV-encoded small RNA or EBV DNA in situ hybridization. In addition, patients were required to have incurable NPC as defined by recurrent/PD after initial treatment or distant metastasis, as well as documented PD before study enrollment and treatment. Patients were ineligible if they had any serious infections or active brain metastases, had received radiotherapy for NPC within 8 weeks of enrollment, or had undergone chemotherapy within 2 weeks of enrollment. Concurrent immunosuppressive therapy was prohibited. An Eastern Cooperative Oncology Group performance status 1 and adequate bone marrow, liver, and renal function were required for eligibility (see Supporting Information Table 1 ). Screening began in February 2007, and the studies were closed to accrual in January 2012.
Generation of EBV-CTLs
After informed consent was obtained, eligible patients underwent a blood draw for preparation of the T-cell immunotherapy product at the Connell and O'Reilly Families Cell Manipulation Core Facility at DFCI. PBMCs were isolated from whole blood, and 5310 6 PBMCs were used to generate patient-specific LCLs by infection with B95-8 EBV in the presence of cyclosporine A. LCLs were expanded to appropriate numbers for LCL-mediated CTL stimulation in media containing 100 lM of acyclovir, which prevented viral replication.
PBMCs (2310 6 /mL) were stimulated with the autologous irradiated LCLs at an effector-to-stimulator ratio of 40:1. After 9 days, viable cells were restimulated at an effector-to-stimulator ratio of 4:1. CTLs were then expanded by weekly LCL stimulation in the presence of interleukin-2 until sufficient numbers of CTLs had been expanded for clinical use. After expansion, the CTLs were cryopreserved in Plasma-Lyte A (Baxter Healthcare Corporation, Deerfield, Ill) containing 2.5% human serum albumin with 10% dimethyl sulfoxide. CTL products were released for clinical use based on testing for sterility, immunophenotype, and lack of autoreactivity.
Study Design
The phase 1 portion of the trial was a pilot feasibility study that provided the basis for further patient accrual on the phase 2 study. There was no dose escalation in the phase 1 portion of the study, and T-cell products had identical manufacturing protocols between the 2 studies. After initial enrollment, obtainment of informed consent, and phlebotomy for T-cell production, all subjects received palliative chemotherapy for NPC as standard of care during the period required for T-cell production. Patients who achieved a PR or CR while receiving this palliative chemotherapy continued to receive chemotherapy for 3 to 6 cycles and were eligible only for immunotherapy when they had PD as confirmed by an additional set of scans.
At the time of confirmed PD during receipt of palliative chemotherapy, each subject was offered 2 EBV-CTL infusions given 2 weeks apart, at doses of 1310 8 cells/m 2 . Eight weeks after the second infusion of EBV-CTL, subjects underwent restaging scans to determine response according to Response Evaluation Criteria In Solid Tumors (RECIST; version 1.1). Patients were eligible for an additional infusion of EBV-CTL (1-2310 8 cells/m 2 ) administered approximately 8 to 12 weeks after the second infusion if additional product was available. Restaging scans were performed every 8 weeks until PD, and subjects were followed for survival. Standard physical examinations, hematology tests, and serum chemistries were followed throughout treatment for each patient. Plasma viral loads (VLs) were measured at an outside laboratory (Focus Diagnostics Inc, Cypress, Calif).
Measuring Clinical Response
Tumor response to the EBV-CTL immunotherapy was measured as PD, SD, PR, or CR by RECIST (version 1.1) scores on scans. To ensure comparability, baseline and restaging scans were interpreted at the central tumor imaging facility at the Dana-Farber/Brigham and Women's Hospital Cancer Center. The response rate was measured by calculating the number of patients who received a clinical benefit (CR or PR) divided by the total number of patients who underwent treatment. Progression-free survival (PFS) was measured from time of first T-cell infusion to PD, and OS was measured from time of first Tcell infusion to either death or date of last patient contact.
Flow Cytometry
Flow cytometry was performed on a FACSCalibur (BD Biosciences, San Jose, Calif) machine with T-cell-specific, fluorescently conjugated antibodies (BioLegend, San Diego, Calif). The phenotypic distribution of the cells then was analyzed with FlowJo software (FlowJo LLC, Ashland, Ore).
Enzyme-Linked Immunospot
The specificity and magnitude of the EBV-CTL response in the T-cell products were measured by interferongamma enzyme-linked immunospot (IFN-c ELISPOT) using overlapping peptide libraries for EBV nuclear antigen 1 (EBNA-1) and EBV latent membrane protein 2 (LMP2), as in Fogg et al. 25 Cells were placed in 96-well plates coated with antihuman IFN-c monoclonal antibody, and then developed according to a commercially available kit (Mabtech, Nacka Strand, Sweden). Spot counting was completed by an automated reader (Carl Zeiss Inc, Thornwood, NY), with KS ELISPOT software (version 4.5; Carl Zeiss Inc). The background values of cells incubated with dimethyl sulfoxide/no peptide subsequently were subtracted from all test samples.
RESULTS
Patient Characteristics, T-Cell Manufacturing, and Immunotherapy Infusions
A total of 28 patients were enrolled in the study (Table 1) , and all but 2 patients had metastatic disease at the time of Cancer initial enrollment (Table 2) . After enrollment, patients had blood drawn for T-cell product manufacturing, and then received palliative chemotherapy as standard care for NPC while their immunotherapy product was being manufactured. The mean time from the initial blood draw to cryopreservation of the final T-cell product was 115 days (range, 83-169 days) (data not shown). T-cell products were generated successfully from all but 1 patient (patient 7). Of the 28 enrolled patients, 21 ultimately became eligible for infusion and received immunotherapy; details regarding the 7 patients who screen failed are listed in Supporting Information Table 2 . Twenty of the 21 treated patients had metastatic disease at the time of enrollment, whereas 1 patient (patient 11) had recurrent locoregional disease with no curative treatment options ( Table 2) .
The mean waiting period from the end of product manufacturing to T-cell infusion was 71 days. Three patients (patients 8, 11, and 15) were infused with their immunotherapy product within 30 days of manufacturing completion because there was rapid PD despite palliative chemotherapy. In 9 patients, infusion was delayed for >60 days (with 1 patient waiting 352 days) after the completion of product manufacturing, due to prolonged clinical responses from palliative chemotherapy (patients 1, 6, 10, 12, 14, 17, 20, 21 , and 22) (data not shown). However, although these interim time periods varied in length, there was no change noted with regard to the quality of the T-cell product because the EBV-CTLs were cryopreserved after expansion.
Characteristics of EBV-CTL Products
The cell products manufactured for the 21 treated patients had an average yield of 1. Table 3 . EBV-specific activity in the T-cell products was assessed in vitro by measuring T-cell activation after exposure to autologous LCLs. Lysosomalassociated membrane protein 1 (LAMP1/CD107a) is Immunotherapy for Nasopharyngeal Cancer/Huang et al
Cancer
July 15, 2017
exposed on the surface of CD8-positive T cells after antigen-specific activation, and thus detection of CD107a cell surface expression by flow cytometry was used as a marker for antigen-specific CD8-positive T-cell activation. Incubation with autologous LCLs induced CD107a surface expression in an average of 52.4% of cells (range, 23.3%-82.2%), whereas incubation with autologous phytohemagglutin (PHA) blasts, acting as a negative control, induced little CD107a surface expression (mean, 1.3% CD107a positive [range, 0.0%-5.9%]) (Table 3) . EBV LCLs express a broader range of latent viral proteins (6 nuclear proteins or EBNAs, and 3 membrane proteins or LMPs) compared with NPC tumor cells, in which viral protein expression is more limited to EBNA-1 and LMP2. 26, 27 To assess how effective the T-cell product might be against the more restricted targets expressed in NPC, we used IFN-c ELISPOT assays to determine the percentage of cells in the T-cell product that recognized the EBNA-1 and LMP2 proteins (Table 3) .
Clinical Response
One patient with metastatic disease achieved a CR after 3 cycles of immunotherapy and was alive at the time of last follow-up without disease recurrence >100 months after infusion (patient 1). Two other patients maintained SD for 18.7 months (patient 18) and 6.5 months (patient 15) after immunotherapy, but other patients demonstrated evidence of PD at the 8-week evaluation time point after EBV-CTL infusion. Thus, the ORR was 4.8%. The median PFS was 2.2 months, and the median OS was 16.7 months (Table 4) . Patients who were lost to follow-up were excluded from calculation of the median OS. Overall, few severe adverse events were observed. However, patient 5 did develop grade 5 sepsis and pulmonary insufficiency, but the death was determined to be due to PD and unrelated to treatment. Study-wide, no adverse events of grade 3 were found to be related to treatment (see Supporting Information Table 3) .
It is interesting to note that patient 8 had a renewed response to gemcitabine after receiving EBV-CTL immunotherapy. Before enrollment, the patient had received carboplatin and gemcitabine as palliative chemotherapy, but progressed quickly after the completion of treatment. Two months after infusion of EBV-CTLs, the patient developed PD while receiving immunotherapy and was started back on gemcitabine monotherapy, which 
EBV VLs
EBV VLs were measured after the initiation of immunotherapy. Of 21 patients who had VLs measured, 6 had undetectable VLs and 15 had measurable VLs at baseline (median, 7621 copies/mL; range, 295-1.55 million copies/ mL). Of the 15 patients with measurable VLs at baseline, 3 had sustained drops from baseline at all measured time points (data not shown). There were no correlations evident between VLs and clinical response or length of PFS.
DISCUSSION
The current study evaluated the effect of EBV-CTL immunotherapy among 21 patients with incurable NPC.
Key aspects of this study included the patient population and the study design. Only one patient had recurrent locoregional disease, whereas all other treated patients had recurrent, metastatic NPC. Patients with recurrent and/or metastatic NPC have a poor prognosis with standard chemoradiotherapy, although a percentage of these individuals will have prolonged responses to initial therapy. Thus, these patients would benefit from novel therapeutic approaches. The current study allowed palliative chemotherapy to be administered during the period of product manufacturing, but required documented PD before immunotherapy to clearly distinguish the potential effects of immunotherapy from prolonged or continued effects of the prior chemotherapy. This requirement added a significant waiting period before the initiation of immunotherapy infusion, with a mean duration of 71 days spent waiting for evidence of PD in addition to an average of 115 days for product manufacturing. The data from the current study demonstrate the potential for responses to palliative chemotherapy despite the poor overall prognosis in this patient population, as well as the importance of separating responses to immunotherapy from those to chemotherapy within the context of clinical trial design. Indeed, 2 patients had sustained responses to palliative chemotherapy that delayed immunotherapy infusion for >100 days and 300 days, respectively, and 2 other patients never received their immunotherapy product because they failed to progress on the interim palliative chemotherapy. Our observation of the patient with a sustained CR was consistent with the antitumor potential of EBVspecific immunotherapy, but our response rate fell short of what to the best of our knowledge is the highest response rate of 48.7% reported in the literature. 24 This difference is unlikely to be due to technical differences in the nature of the T-cell products because we used the same manufacturing process as those prior studies. In addition, the EBNA-1-specific and LMP2-specific T-cell responses in our products were comparable to those reported by those same studies. 23, 24 Approximately 24% of our T-cell product lines had EBNA-1-specific CTLs, compared with 31% (5 of 16 tested) as described by Louis et al. 24 Although EBNA-1 specificity may appear to be slightly lower in the current study, it may be explained by differences in patient populations between the 2 studies. The study by Fogg et al proposed that EBNA-1-specific T cells may be suppressed by regulatory T cells. 25 Because our entire patient population had incurable disease and no patients were in remission, it is possible that the patients in the current study may have been more likely to experience significant regulatory T-cell suppression of EBNA-1. LMP2-specific CTLs also were detected at a comparable frequency from products manufactured at both sites: 71% of lines in the current study versus 73% at the Baylor College of Medicine. 24 The magnitude of the LMP2-specific CTL response in our T-cell products (average of 1177 spot-forming cells [ sfc]/10 6 cells; data not shown) appeared lower than what was previously published by Straathof et al (average of 5445 sfc/10 6 cells). 23 However, there were technical differences in the approach used to measure LMP2-specific CTL responses. We used a pool of peptides spanning the entire LMP2 protein population, whereas Straathof et al used specific peptides for optimally defined LMP2 epitopes restricted by 1 of 7 human leukocyte antigen (HLA) alleles (A2, A11, A23, A24, A68, B27, and B60). 23 To address this potential difference, we applied the same approach with specific peptides for 8 LMP2 epitopes restricted through 3 HLA alleles (A2, A23, and A24). The average LMP2-specific CTL response in 7 T-cell products from patients with the appropriate HLA background was 2220 sfc/10 6 cells, which was nearly double the average obtained using a pool of LMP2 peptides. Thus, using specific peptides versus large peptide pools is more sensitive. In addition, flow cytometry analysis of the T-cell product from an HLA A23-positive patient, using a tetrameric HLA A23 complexed with an HLA A23-restricted epitope from LMP2, demonstrated LMP2 staining in 3.42% of cells (data not shown), which is within the same range as reported previously. 23 With these analyses, the frequency, breadth, and magnitude of the EBNA-1-specific and LMP2-specific CD8-positive T-cells in the immunotherapy products were comparable to those reported previously from other centers. 23, 24 One explanation for this discrepancy in response rates may instead lie in the differences in clinical trial design. In contrast to some prior studies, the current study required patients to have confirmed PD before the initiation of immunotherapy so that we could distinguish responses to prior palliative chemotherapy from those to investigational immunotherapy. This is especially important within the context of incurable NPC because these patients exhibit a wide variability in survival while receiving palliative chemotherapy.
Previous studies also have proposed a prognostic scoring model using clinical parameters such as lactate dehydrogenase level, EBV DNA copies, and Eastern Cooperative Oncology Group performance status as prognostic markers for NPC, and it would be interesting to determine whether this model could help to explain the differences in the ORR between studies. 28 However, the practical use of this scoring model to compare response rates between the current study and prior studies would be difficult at this time because to our knowledge studies regarding T-cell immunotherapy for NPC have not yet used this model.
Finally, clinical differences in NPC populations are likely to be important determining factors for response rates to immunotherapy. All but one of the treated patients in the current study had metastatic disease. When Louis et al 24 followed up with their phase 1 study from Straathof et al, 23 they focused on the patient population with metastatic disease as well. In that study, Louis et al reported a much lower response rate in the incurable population, with only 1 of 11 patients exhibiting a long-term response. 24 Comoli et al 22 also reported only 2 cases of brief PRs with no long-term responses among 10 patients with metastatic NPC, although a different dosing schedule composed of more frequent, smaller doses make a direct comparison difficult. Smith et al 2 used an adenovirusbased vector to generate T-cell products with more EBNA-1-specific and LMP2-specific activity, but there were no documented clinical responses reported among 24 patients with NPC with metastatic disease. The median PFS and OS were increased to 2.2 months and 17.4 months, respectively, in treated versus nontreated patients, which was similar to observations in the current study (median PFS and OS of 2.2 months and 16.7 months, respectively). 2 The overall experience indicates that response rates to immunotherapy are low in patients with incurable NPC and that immunotherapy products with more potent anti-EBV activity will be required for the treatment of this patient population. It also may be worthwhile to explore combination regimens with other immune modulators such as checkpoint inhibitors or drugs targeting regulatory T cells to enhance the efficacy of EBV-specific T cells. 29 The phenomenon of a renewed response to chemotherapy after PD while receiving EBV-CTL immunotherapy was observed in 2 patients in the current study who had renewed, robust responses to the same chemotherapy agents they had previously failed (one with docetaxel and another with gemcitabine). One may speculate from these observations that perhaps the immunotherapy diminished the cancer's previously acquired resistance to these chemotherapies, or that the immunotherapy interacted with or primed the patient's immune system to confer a greater response to the chemotherapy. These observations, supported by results from other past studies, suggest that there also might be a role for EBV-CTL immunotherapy as a primer for, or in combination therapy with, chemotherapy. 2, 23 Indeed, in one study published in 2014, firstline treatment for patients with metastatic or locally recurrent NPC with chemotherapy followed by adoptive T-cell immunotherapy demonstrated increased OS compared with historical chemotherapy treatment controls. 30 In this context, further studies could incorporate chemotherapy for patients after they have failed both the first chemotherapy and immunotherapy to observe for potential renewed responses to chemotherapy.
One additional avenue for improving T-cell therapy strategies can be found in the T-cell manufacturing process. Although using LCLs in generating our product provided a potent stimulation for EBV-specific T cells, a drawback was the length of time needed to produce EBVCTLs. Future studies incorporating an adoptive T-cell immunotherapy in patients with NPC can consider adding other stimuli (such as cytokines and growth factors) or removing inhibitory effects (such as regulatory T cells) to generate more potent T-cell products in a shorter period of time.
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